|
1
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al; Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group, . Fluorouracil versus combination of irinotecan
plus cisplatin versus S-1 in metastatic gastric cancer: A
randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al; ToGA Trial Investigators, . Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom, . Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah MA, Bang YJ, Lordick F, Alsina M,
Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, et al:
Effect of fluorouracil, leucovorin, and oxaliplatin with or without
onartuzumab in HER2-negative, MET-positive gastroesophageal
adenocarcinoma: The METGastric randomized clinical trial. JAMA
Oncol. 3:620–627. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoon HH, Bendell JC, Braiteh FS, Firdaus
I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz
JD, et al: Ramucirumab combined with FOLFOX as front-line therapy
for advanced esophageal, gastroesophageal junction, or gastric
adenocarcinoma: A randomized, double-blind, multicenter Phase II
trial. Ann Oncol. 27:2196–2203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurokawa Y, Sugimoto N, Miwa H, Tsuda M,
Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, et
al: Phase II study of trastuzumab in combination with S-1 plus
cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer.
110:1163–1168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miura Y, Sukawa Y, Hironaka S, Mori M,
Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K,
et al: Five-weekly S-1 plus cisplatin therapy combined with
trastuzumab therapy in HER2-positive gastric cancer: A phase II
trial and biomarker study (WJOG7212G). Gastric Cancer. 21:84–95.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al; RAINBOW Study Group, . Ramucirumab plus paclitaxel versus
placebo plus paclitaxel in patients with previously treated
advanced gastric or gastro-oesophageal junction adenocarcinoma
(RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol.
15:1224–1235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
American Society of Clinical Oncology:
Outcomes of cancer treatment for technology assessment and cancer
treatment guidelines. J Clin Oncol. 14:671–679. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greer JA, Pirl WF, Jackson VA, Muzikansky
A, Lennes IT, Heist RS, Gallagher ER and Temel JS: Effect of early
palliative care on chemotherapy use and end-of-life care in
patients with metastatic non-small-cell lung cancer. J Clin Oncol.
30:394–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito AM, Landrum MB, Neville BA, Ayanian
JZ and Earle CC: The effect on survival of continuing chemotherapy
to near death. BMC Palliat Care. 10:142011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Näppä U, Lindqvist O, Rasmussen BH and
Axelsson B: Palliative chemotherapy during the last month of life.
Ann Oncol. 22:2375–2380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lewin SN, Buttin BM, Powell MA, Gibb RK,
Rader JS, Mutch DG and Herzog TJ: Resource utilization for ovarian
cancer patients at the end of life: How much is too much? Gynecol
Oncol. 99:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Temel JS, Greer JA, Muzikansky A,
Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD,
Jacobsen J, Pirl WF, et al: Early palliative care for patients with
metastatic non-small-cell lung cancer. N Engl J Med. 363:733–742.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bjordal K and Aass N: Palliative
cytostatic treatment. Tidsskr Nor Laegeforen. 124:3206–3207.
2004.(In Norwegian). PubMed/NCBI
|
|
22
|
Hemminki K and Chen B: Familial risk for
colorectal cancers are mainly due to heritable causes. Cancer
Epidemiol Biomarkers Prev. 13:1253–1256. 2004.PubMed/NCBI
|
|
23
|
Kim A, Fall P and Wang D: Palliative care:
Optimizing quality of life. J Am Osteopath Assoc. 105 Suppl
5:S9–S14. 2005.PubMed/NCBI
|
|
24
|
Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im
SA, Kim TY, Bang YJ and Heo DS: Aggressiveness of cancer-care near
the end-of-life in Korea. Jpn J Clin Oncol. 38:381–386. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakano K, Yoshida T, Furutama J and Sunada
S: Quality of end-of-life care for patients with metastatic
non-small-cell lung cancer in general wards and palliative care
units in Japan. Support Care Cancer. 20:883–888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peppercorn JM, Smith TJ, Helft PR, Debono
DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH and Schnipper LE;
American Society of Clinical Oncology, . American society of
clinical oncology statement: Toward individualized care for
patients with advanced cancer. J Clin Oncol. 29:755–760. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahsan H, Neugut AI, Garbowski GC, Jacobson
JS, Forde KA, Treat MR and Waye JD: Family history of colorectal
adenomatous polyps and increased risk for colorectal cancer. Ann
Intern Med. 128:900–905. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hashimoto K, Yonemori K, Katsumata N,
Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M and
Fujiwara Y: Factors that affect the duration of the interval
between the completion of palliative chemotherapy and death.
Oncologist. 14:752–759. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asola R, Huhtala H and Holli K: Intensity
of diagnostic and treatment activities during the end of life of
patients with advanced breast cancer. Breast Cancer Res Treat.
100:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thorne SE, Bultz BD and Baile WF; SCRN
Communication Team, . Is there a cost to poor communication in
cancer care?: A critical review of the literature. Psychooncology.
14:875–884; discussion 885-886. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyamoto T, Ogawa M, Okagawa K, Ogawa Y,
Fujimoto J, Kawasaki K, Mizunoya S, Fujiyama T, Kido Y, Shiozaki H,
et al: The histological types of eary and simulating advanced
gastric cancer, and their clinicopathological character -with
special refemence to lymphnode metastasis and lymphatic invasion.
Nihon Shokaki Geka Gakkai Zasshi. 16:1772–1777. 1983.(In
Japanese).
|
